

# Outcome following Necrotizing Pancreatitis

Satya Prasad Samantaray<sup>1</sup>, Nihar Ranjan Dash<sup>2</sup>, Sujoy Pal<sup>3</sup>, Peush Sahni<sup>4</sup>, T K Chattopadhyay<sup>5</sup>, Pramod Garg<sup>6</sup>

<sup>1</sup>Assistant Professor, Dept. of Surgical Gastroenterology, SCB Medical College, Cuttack-753007, Odisha, India

<sup>2, 3, 4, 5, 6</sup>Department of G.I. Surgery and Liver Transplantation and Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi

**Abstract:** ***Objective:** To study the long term outcome following recovery from acute necrotizing pancreatitis in terms of structural and functional status of pancreas (both exocrine and endocrine) and to study the correlation, if any, of the long-term consequences with respect to the severity of necrotizing pancreatitis and between the groups of patients managed conservatively and operatively. **Methods:** All patients with a diagnosis of acute necrotizing pancreatitis based on Balthazar CT severity index (CTSI) in AIIMS, New Delhi following recovery of the illness were included in the study between the period from March, 2011 to June, 2012. Patients managed both operatively and nonoperatively were followed up at six months and at one year. Structural changes were assessed by ultrasound at 6 months and 1 year. CECT scan/ MRI with MRCP/ ERCP/ EUS were done if ultrasound reveals any abnormality. Exocrine function of pancreas was assessed by fecal fat and stool elastase and endocrine function by fasting blood sugar, fasting serum c-peptide and HbA1c levels. **Results:** Pancreatic atrophy was more in the operated patients compared to nonoperated patients at discharge and at 6 months of follow up. Pancreatic exocrine and endocrine insufficiency, were similar in both groups. **Conclusion:** There was a high correlation between extent of necrosis and subsequent development of pancreatic atrophy and diabetes in both groups of patients. Exocrine and endocrine functions deteriorate after necrotizing pancreatitis irrespective of conservative or operative treatment and there is no statistically significant difference between the two modes of treatment.*

**Keywords:** Necrotizing pancreatitis, Pancreatic atrophy, Exocrine function, Endocrine function

## 1. Introduction

Acute pancreatitis can be non-necrotizing with an acute inflammatory process of the gland with interstitial edema (interstitial edematous pancreatitis), or it can be necrotizing. Pancreatic necrosis occurs in approximately 20% of patients with acute pancreatitis[1]. Necrotizing variety can take 2 forms - 1. peripancreatic necrosis alone and 2. pancreatic necrosis with or without peripancreatic necrosis, which constitutes 80% of patients with necrotizing pancreatitis. Necrotizing pancreatitis can have diffuse or focal area(s) of non-viable pancreatic parenchyma; it can be sterile or infected and is always associated with a possible damage to the pancreas. The initial (< 1 week) solid necrosis liquefies by a process of liquefaction necrosis and later (>4 weeks) a more semi-solid, non-homogenous appearance is common. So, in the later stages of necrosis, the content may be predominantly pus in addition to some solid components, as the process of liquefaction necrosis matures.

In pancreatic necrosis when the non-enhanced pancreatic parenchyma is >3 cm or involves > 30% of the area of the pancreas, exocrine and endocrine functions are impaired to a variable degree for a variable duration. If necrosis involves a segment of the main pancreatic duct, stenosis may result, leading to obstructive chronic pancreatitis distal to the site of necrosis or 'disconnected-duct syndrome'. It is not clear when functional changes resolve and to what degree [2]

## 2. Objective

To study the long term functional outcome following recovery from acute necrotizing pancreatitis in terms of

- Structural change
- Exocrine function status
- Endocrine function status

- To study the correlation, if any, of the long-term consequences with respect to the severity of necrotizing pancreatitis and between the groups of patients managed conservatively and operatively

## 3. Methods

After approval from ethical committee of AIIMS, New Delhi, patients were recruited in the study. All patients with a diagnosis of acute necrotizing pancreatitis following recovery of the illness were included in the study between the period from March, 2011 to June, 2012.

Patients underwent detailed history and clinical examination. Demographic details (age, sex, weight, body mass index) were noted, etiology was assessed and patients were evaluated with standard laboratory investigations (haemogram, renal function test, and liver function test), specific laboratory investigations (lipase/amylase in case of abdominal pain and triglycerides in case of recurrent episodes of pain). Patients managed both operatively and nonoperatively were followed up at six months and at one year to look into the structural and functional aspects of pancreas.

### Inclusion Criteria

All patients with diagnosis of acute necrotizing pancreatitis based on Balthazar CT severity index (CTSI) who were managed by conservative or surgical means, following recovery of their illness, were included[3]. The date of recovery was considered as the date of discharge following the index admission for acute necrotizing pancreatitis in the Department of Gastroenterology in case of conservative management and date of necrosectomy in case of patients undergoing surgical treatment. All such patients were included.

**Exclusion Criteria**

- Patients who refused to give consent
- Patients with documented or suspected chronic pancreatitis based on history of chronic alcohol intake, profound loss of weight or other symptoms suggestive of chronic pancreatitis like steatorrhea
- Pancreatic head cancer leading to pancreatitis
- Surgery other than pancreatic necrosectomy following acute necrotizing pancreatitis
- Patients with severe systemic disease (cardiovascular or respiratory)
- History of diabetes mellitus prior to acute necrotizing pancreatitis
- Patients who did not come for follow up

**4. Outcome**

**(A) Structural changes**

The structural changes were assessed by doing an ultrasound at 6 months and 1 year. In case any abnormality was detected on ultrasound, appropriate further investigations such as contrast-enhanced computed tomography (CECT scan)/ magnetic resonance imaging with magnetic resonance cholangiopancreatography (MRI with MRCP)/endoscopic retrograde cholangiopancreatography (ERCP)/ endoscopic ultrasound (EUS) were done.


**(B) Functional changes**

Functional outcome was assessed by evaluating the exocrine and endocrine functions of pancreas in these participants. Fecal fat and stool elastase estimation were done for exocrine function. Fasting blood sugar, fasting serum c-peptide and HbA1c levels were measured for evaluating endocrine function. Weight and nutritional parameters such as serum albumin were measured. Need for pancreatic enzyme supplementation and oral hypoglycemics or insulin was noted. Height and BMI were also recorded. Data of patients managed conservatively and those managed surgically were compared.

**Statistical Methods**

Data was entered in a Microsoft Excel worksheet and statistical analysis was done using SPSS-15 soft ware (ILLINOIS Chicago, USA). Data was expressed as mean ± Standard Deviation. Chi-square test / Fisher’s exact test was used for comparing dichotomous data. Paired-t test / Wilcoxon signed rank test was used to compare measured data of paired samples. Independent variable t-test / Mann Whitney U test was used for comparing measured data of unrelated samples. A p value of 0.05 or less was taken as significant.

**5. Results and Discussion**



**Figure 1:** Clinical Profile of patients with acute pancreatitis

One hundred seventy four patients with acute pancreatitis were studied during the period from March 2011 to June 2012. Out of the 129 patients with necrotizing pancreatitis, 91 patients were followed up from the time period between February 2011 to June 2012. Out of the 91 patients, 56 patients had undergone conservative management and 35 patients had surgery. Following tables are related to the data of these 91 patients.

**1) Demography and Etiology**

Patient subgroup managed conservatively in this study were significantly older than those who underwent surgery (mean age 40.9 ± 13.8 years versus 33±12.4 years), which is statistically significant. Male gender was affected commonly (72.6%) in both operated and nonoperated patients which is supported by other studies as well[4].

Biliary etiology was found to be the commonest in both nonoperated (46.4%) and operated groups (57.1%) followed by alcohol in operated (20%) and idiopathic in nonoperated groups (26.7%). Overall biliary etiology was most common (50.5%) followed by alcohol (23%) and idiopathic cause (21.9%). Literature review reveals similar findings. Fernandez-Cruz *et al.*, reviewed 233 patients with acute necrotizing pancreatitis and found 45.5% of their patients were of biliary etiology[5]. Similarly bile duct stones and alcohol abuse together accounted for about 80% of acute pancreatitis in the study by Sakorafas *et al*[6].

**2) Nutritional, exocrine and endocrine parameters**

**Table I:** Nutritional, exocrine and endocrine parameters

Parameters	Operated	Nonop.	Operated	Nonop.	operated	Nonop.
	Discharge		6 months		1 Year	
FBS (mg/dl)	105.1 ±16.8	117±49.8	111.2±38.2	147.0±100.4	156.7±97.8	151.1±122.5
C-peptide (ng/ml)	3.8±2.9	3.3±1.2	2.5±1.3	2.8±1.3	5.1±0.9	3.0±1.2
HbA1c (%)	5.1±0.9	5.4±1.6	5.6±1.6	6.6±2.8	6.6±2.8	6.7±2.9
Diabetes	26%	26.40%	30%	35.40%	33.30%	45.40%
elastase (µg/g stool)	41.5±32.5	96±83.4	74.2±50.4	36.7±35	94.8±67.0	69.4±55.3
Fecal fat (g/24 hrs)	5.23±5.8	5.2±3.3	3.7±3.4	4±2.5	10.1±19.5	21±85.5
Albumin (mg/dl)*	3.3±0.6	3.3±0.63	4.6±0.5	4.0±0.8	4.9±0.4	4.7±0.4
BMI	17.8±3.1	19.6±4.0	21.1±2.8	21.9±3.5	22.7±3.3	23.9±5.5

FBS- Fasting blood sugar; HbA1c- Glycosylated haemoglobin; BMI- Body Mass Index; \* P< 0.05

Mean weight of the patients at 6 months ( $59.5 \pm 8.9$  kg) and one year ( $64.7 \pm 11.6$  kg) following discharge were significantly higher (p value 0.003) compared to the weight at discharge ( $52.3 \pm 10.1$  kg) in both groups of patients. All patients in the operated group and all but two patients in the nonoperated group had gained weight at one year compared to weight at 6 months. Weight of the patients at discharge showed a statistical difference (p value 0.018) according to the extent of pancreatic necrosis. Mean weight of patients at discharge was 47.0 kg in the group of patients with <30% pancreatic necrosis versus 55.9 kg in patients with extent of pancreatic necrosis > 50%. Johnson *et al.*, also observed a more severe disease in overweight patients[7]. There was an increase in serum albumin level at 6 months ( $4.3 \pm 0.78$  mg/dl) and one year ( $4.8 \pm 0.48$  mg/dl) following recovery of the illness in both groups of patients, and increase was highly significant. The difference of serum albumin at 6 months following recovery between the two groups was significant statistically, and rise in serum albumin was more in the operated group.

Diarrhea was present in four patients each in either group, constituting 14.03% (8/57) of total patients studied. At follow up at 6 months and one year, 7.8% (4/51) and 11.1% (4/36) patients had diarrhea respectively. Pancreatic exocrine deficiency manifesting as diarrhea is not an unusual outcome following acute necrotizing pancreatitis. Our experience from this study reveals diarrhea rate of 14.03%, 7.8% and 11.1% of patients at the time of discharge, at 6 months and at one year respectively. Literature review suggests diarrhea in one-fourth to more than half of patients[8,9].

### 3) Fecal fat and elastase

**Table II: Fecal fat and elastase value**

Both op. and nonop. patients	Fecal fat (g/24 hrs)	P value	Fecal elastase ( $\mu\text{g/g}$ stool)	P value
At discharge	$5.64 \pm 5.6$	0.745	$31.71 \pm 26.7$	
At 6 months	$3.83 \pm 3.0$	0.529	$100 \pm 54.8$	0.028
At 1 year	$7.5 \pm 16.2$	0.49	$169 \pm 41.0$	0.18

Fecal fat test is a diagnostic test for fat malabsorption, due to deficiency of pancreatic lipase which leads to excess fat in the feces (steatorrhea). The normal value of fecal fat is < 7g/24 hours stool. In the nonoperated group, 7 to 28% of patients had excessive fecal fat level at different times of follow up and in the operated group this was between 7 to 18%. There was no statistically significant difference between the two groups.

Severe exocrine pancreatic insufficiency was considered when the elastase level was <100  $\mu\text{g/g}$  stool and moderate when it was 100-200  $\mu\text{g/g}$  stool. Fecal elastase was severely reduced in both groups of patients. There was slight increase in elastase level at 6 months, and the increase between the two groups was statistically significant; the increase being more in favour of operated group. At one year follow up there was no difference in the increase in level between the two groups.

### 4) Enzyme supplementation and development of diabetes

**Table III: Enzyme supplementation**

Enzyme supplementation	Nonop. patients	Operated patients	Total	P value
At discharge	3/34(8.8%)	4/23(17.3%)	7/57(12.2%)	0.423
At 6 months	3/31(9.6%)	1/20(5%)	4/51(7.8%)	1
At 1 year	3/24(12.5%)	1/12(8.3%)	4/36(11.1%)	1.03

**Table IV: Development of diabetes**

Development of diabetes	Nonop. patients	Operated patients	Total	P value
During illness	18/56(32.1%)	8/35(22.8%)	26/91(28.5%)	0.475
At discharge	9/34(26.4%)	6/23(26%)	15/57(26.3%)	0.497
At 6 months	11/31(35.4%)	6/20(30%)	17/51(33.3%)	0.463
At 1 year	10/22(45.4%)	4/12(33.3%)	14/34(41.1%)	0.377

**Table V: Extent of necrosis and laboratory parameters**

	Discharge				6 months				1 year			
	<30%	30-50%	>50%	Total	<30%	30-50%	>50%	Total	<30%	30-50%	>50%	Total
Necrosis (%)												
Diabetes	4	2	9	15	5	3	9	17	6	3	5	14
F.Elastase e<100 $\mu\text{g/g}$ stool	2	1	7	10	5	3	6	14	5	3	6	14
Albumin (mg/dl)	$3.1 \pm 0.5$	$3.5 \pm 0.4$	$3.3 \pm 0.7$		$4 \pm 0.6$	$4.1 \pm 0.8$	$4.6 \pm 0.7$		$4.8 \pm 0.4$	$4.6 \pm 0.6$	$5.0 \pm 0.3$	

Enzyme supplementation was needed in only 12.2, 7.8 and 11.1% of patients at discharge, 6 months and 1 year respectively. The difference in use of the pancreatic enzymes in both groups was not statistically significant. Bavare *et al.*, found 11% of of their post necrosectomy requiring enzyme supplementation after 18 months follow up[10].

It has long been known that endocrine pancreatic function is impaired during and after an attack of acute necrotizing pancreatitis. Some 25-40% of our patients developed diabetes mellitus in the follow up period and there was no statistical difference between the two groups of patients. Other studies also reveal similar results[7]. We also observed that 60% (9/15) of the patients developing diabetes



mellitus at discharge and 52% (9/17) at 6 months had more than 50% of pancreatic necrosis.

**5) Hb1Ac**

**Table VI: Hb1Ac**

Both op. and nonop. patients	HbA1c (%)	P value
At discharge	5.5 ± 1.22	
At 6 months	6.24 ± 2.4	0.030 (HbA1c discharge vs at 6 months)
At 1 year	6.97 ± 3.12	0.000 (HbA1c at discharge vs at 1 year)

HbA1c levels were found to be elevated in increased number of patients at the time of discharge, at 6 months and at 1 year respectively in both groups of patients, implying that the number of patients developing diabetes increase over time (the normal value of HbA1c in our laboratory is 4.27-6.07%). There was no statistically significant difference in elevated HbA1c levels between the two groups of patients.

Uomo *et al.*, also found that with increased duration of follow up, the prevalence of diabetes in the post acute necrotizing pancreatitis patient population increases[11]. Wu *et al.*, observed only 8% of his 59 patients with abnormal glycosylated hemoglobin level after an attack of pancreatitis although 32% were found to have elevated fasting blood glucose. This means that the onset of diabetes was new in these patients and they are prone to have increased levels of glycosylated haemoglobin at a later follow up[12].

**6) C-peptide**

**Table VII: C-peptide**

Both op. and nonop. patients	Serum c-peptide (ng/ml)	P value
At discharge	3.93 ± 2.48	
At 6 months	2.79 ± 1.31	0.003 (c-peptide at discharge vs at 6 months)
At 1 year	2.93 ± 1.55	0.379 (c-peptide at discharge vs at 1 year)

Most of the patients got their c-peptide done in our series and the values were largely within normal range (1.1 to 4.4 ng/ml) at discharge and follow ups in both groups. Increased levels of c-peptide in nonoperated and operated groups at one year follow up in our series was 21.7% and 8.3% respectively and decreased levels of c-peptide was found in 17.3% and 8.3% of patients respectively. Buscher *et al.*, found increased basal level of c-peptide in patients undergoing conservative management of acute necrotizing pancreatitis[13]. Similar findings were also obtained by Tsiotos *et al.*, after acute pancreatitis[14]. The difference in findings might well be attributable to the complex equilibrium between the amount of beta cell loss leading to decrease in serum c-peptide level versus the development of secondary diabetes due to peripheral insulin resistance and consequent increase in serum c-peptide level.

**7) Oral hypoglycaemic agent (OHA) and insulin use**

One patient from each group required OHA at the time of discharge, at 6 months and at 1 year. Percentage of nonoperated patients dependent on insulin at the time of discharge, at 6 months and at 1 year were 14.7%, 22.5%, 20.8% respectively. The same figures in case of operated patients were 11.1%, 15% and 25% respectively. There was no statistical difference between two patient groups in terms of insulin requirement.

**8) Structural abnormalities**

**Table VIII: Structural abnormalities**

Type of complication		Duration of follow up		
		Discharge	6 months	1 year
Peripancreatic collection/pseudocyst	Nonop	24/34(70.5%)	15/34(44.1%)	16/34(47.0%)
	Operated	6/23(26.0%)	2/23(8.6%)	0/23
	Total	30/54(55.5%)	17/57(29.8%)	11/35(31.4%)
	P value	0.001	0.004	0.000
Pancreatic atrophy	Nonop	0/34	3/34(8.8%)	9/34 (26.4%)
	Operated	8/23 (34.7%)	10/23(43.4%)	8/23(34.7%)
	Total	8/57 (14.0%)	13/57(22.8%)	17/57(29.8%)
	P value	0.000	0.002	0.5
	Nonop with necrosis score 6		0	2/3 (66.3)
	Operated with necrosis score 6	5/8 (62.5%)	6/10 (60%)	6/8 (75%)
Total	5/8 (62.5%)	8/13 (61.5%)	12/17 (70.5%)	
P value	-	1	1	
Locoregional complications	Nonop	3/34(8.8%)	1/34(2.9%)	3/34 (8.8%)
	Operated	3/23(13.0%)	3/23(13.0%)	4/23 (17.3%)
	Total	6/57(10.5%)	4/57(7.0%)	7/57(12.2%)
	P value	0.945	0.35	0.578

The number of patients with collection or pseudocyst was markedly less in operated patients compared to nonoperated patients at all stages of follow up and the difference between them was statistically significant.

Pancreatic atrophy was statistically significant in operated patients compared to nonoperated patients at discharge and at 6 months, though there was no difference at 1 year of follow up.

We found a high correlation between extent of necrosis and subsequent development of pancreatic atrophy in both group of patients at all stages of follow up and the difference between them was statistically not significant.

Locoregional complications occurred in a fewer number of patients and there was no statistical difference between two groups of patients. The range of locoregional complications varied from dilated main pancreatic duct, splenic vein thrombosis, splenomegaly, splenic hilar collaterals, pleural effusion (unilateral/ bilateral), ascites etc. Most of them were kept on follow up except for tapping pleural effusion and ascites.

### 9) Imagings

Only few patients required cross-sectional imagings at follow up, barring ultrasound of the abdomen and there was no statistical difference between the two groups. The numbers were 7/57 (12.2%) at discharge, 3/51 (5.8%) at 6 months and 3/36 (5.3%) at 1 year. These included CT scan and MRI with MRCP. One patient underwent ERCP and stenting of the pancreatic duct and one patient underwent endoscopic ultrasound.

### 10) Mortality

Mortality rate was 39.2% (22/56) in nonoperated group and 34.2% (12/35) in operated group and there was no statistical difference between the two groups. Although newer modalities of management of acute necrotizing pancreatitis are in vogue, reduction in mortality by any particular management option is not yet answered

## 6. Conclusion

This clinical paradigm 'functional outcome following necrotizing pancreatitis' is not adequately addressed in literature. We studied two groups of patients, i.e., patients managed by conservative means and managed by surgery, and compared the outcomes of both. Nonoperated patients were older than the operated group (mean age 40.9 years versus 30 years). 67.8% of nonoperated patients and 80% of operated patients were males. Biliary etiology was most common (50.5%) followed by alcohol (23%) and idiopathic cause (21.9%). Mortality was high but comparable in both groups (39.2% versus 36.3%). Difference in the outcome among these groups was noted in the following parameters. Peripancreatic collections and/or development of pseudocysts remained higher in the nonoperated group in the follow up period (72%, 45%, and 48% at discharge, 6months, and 1 year versus 22%, 10%, and 0% at 1 year). Pancreatic atrophy was more in the operated patients compared to nonoperated patients at discharge and at 6 months, though there was no difference at 1 year of follow up. Performance status at discharge was better in the nonoperated group.

Other outcomes were similar in both groups. Nutrition parameters like weight and albumin improved at follow up visits. Pancreatic exocrine insufficiency manifesting as diarrhea was noted in 10-15% of patients. Fecal fat level was increased in 10-25% of patients. All patients had low levels of fecal elastase. Severe exocrine pancreatic insufficiency was found in 80% of patients and moderate insufficiency in 20%. 7-12% of patients needed pancreatic enzyme supplementation. 25-40% of our patients developed diabetes mellitus in the follow up period and there was no statistical difference between the two groups of patients. We also observed that 60% (9/15) of the patients developing diabetes mellitus at discharge and 52% (9/17) at 6 months had more than 50% of pancreatic necrosis. Alteration in serum C-peptide level was found in 15-40% of patients. Insulin was used for the treatment of diabetes in 15-20% of patients. Only 1 patient in each group needed oral hypoglycaemic agent for glycaemic control. Pancreas was found to be atrophic in 10-30% of patients. Pancreatic atrophy was statistically significant in operated patients compared to

nonoperated patients at discharge and at 6 months, though there was no difference at 1 year of follow up.

We also observed that 60% (9/15) of the patients developing diabetes mellitus at discharge and 52% (9/17) at 6 months had more than 50% of pancreatic necrosis.

## References

- [1] Bradley, E.L., 3rd and K. Allen, *A prospective longitudinal study of observation versus surgical intervention in the management of necrotizing pancreatitis*. Am J Surg, 1991. **161**(1): p. 19-24; discussion 24-5.
- [2] Gupta, R., et al., *Severe acute pancreatitis: the life after*. J Gastrointest Surg, 2009. **13**(7): p. 1328-36.
- [3] Balthazar, E.J., et al., *Acute pancreatitis: Value of CT in establishing prognosis*. Radiology, 1990. **174**: p. 331-336.
- [4] Anderson, F., et al., *Acute pancreatitis: demographics, aetiological factors and outcomes in a regional hospital in South Africa*. S Afr J Surg, 2008. **46**(3): p. 83-9.
- [5] Fernandez-Cruz, L., et al., *Acute necrotizing pancreatitis: a multicenter study*. Hepatogastroenterology, 1994. **41**(2): p. 185-9.
- [6] Sakorafas, G.H. and A.G. Tsiotou, *Etiology and pathogenesis of acute pancreatitis: current concepts*. J Clin Gastroenterol, 2000. **30**(4): p. 343-56.
- [7] Imrie, C.W., *Prognosis of acute pancreatitis*. Ann Ital Chir, 1995. **66**(2): p. 187-9.
- [8] Connor, S., et al., *Early and late complications after pancreatic necrosectomy*. Surgery, 2005. **137**(5): p. 499-505.
- [9] Reddy, M.S., et al., *Morphological and functional outcome after pancreatic necrosectomy and lesser sac lavage for necrotizing pancreatitis*. Indian J Gastroenterol, 2007. **26**(5): p. 217-20.
- [10] Bavare, C., R. Prabhu, and A. Supe, *Early morphological and functional changes in pancreas following necrosectomy for acute severe necrotizing pancreatitis*. Indian J Gastroenterol, 2004. **23**(6): p. 203-5.
- [11] Uomo, G., et al., *Pancreatic functional impairment following acute necrotizing pancreatitis: long-term outcome of a non-surgically treated series*. Dig Liver Dis. **42**(2): p. 149-52.
- [12] Wu, D., et al., *Endocrine pancreatic function changes after acute pancreatitis*. Pancreas. **40**(7): p. 1006-11.
- [13] Buscher, H.C., et al., *Beta-cell function of the pancreas after necrotizing pancreatitis*. Dig Surg, 1999. **16**(6): p. 496-500.
- [14] Tsiotos, G.G., E. Luque-de Leon, and M.G. Sarr, *Long-term outcome of necrotizing pancreatitis treated by necrosectomy*. Br J Surg, 1998. **85**(12): p. 1650-3.